2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6299 Real-world outcomes of anti-CD38–based quadruplet versus triplet therapy in patients aged ≥75 years with newly diagnosed multiple myeloma

Maria Gavriatopoulou, MD, Ioannis Ntanasis-Stathopoulos, MD2, Panagiotis Malandrakis, MD, MSc, PhD3, Ilias Katsadouros, MD4, Panagiotis Boutsikos, MD5, Eirini Solia, MD6, Foteini Theodorakakou, MD7, Evangelos Eleutherakis-Papaiakovou8, Nikolaos Kanellias, MD, PhD9, Aikaterini Vlachou10, Konstantinos Giannakas, MD11, Aikaterini Nikolopoulou, MD12, Magdalini Migkou13, Evangelos Terpos, MD14, Meletios-Athanasios (Thanos) C. Dimopoulos, MD15, Efstathios Kastritis, MD16
1 National and Kapodistrian University of Athens, Athens, Greece
2 National and Kapodistrian University of Athens, Athens, Greece
3 National and Kapodistrian University of Athens, Athens, Greece
4 National and Kapodistrian University of Athens, Athens, Greece
5 National and Kapodistrian University of Athens, Athens, Greece
6 National and Kapodistrian University of Athens, Athens, Greece
7 National and Kapodistrian University of Athens, Athens, Greece
8 National and Kapodistrian University of Athens, Athens, Greece
9 National and Kapodistrian University of Athens, Athens, Greece
10 National and Kapodistrian University of Athens, Athens, Greece
11 National and Kapodistrian University of Athens, Athens, Greece
12 National and Kapodistrian University of Athens, Athens, Greece
13 National and Kapodistrian University of Athens, Athens, Greece
14 National and Kapodistrian University of Athens, Athens, Greece
15 National and Kapodistrian University of Athens, Athens, Greece
16 National and Kapodistrian University of Athens, Athens, Greece

Background: Patients with multiple myeloma (MM) aged ≥75 years present unique management challenges due to frailty, comorbidities, and elevated treatment-related toxicity risks. While anti-CD38 monoclonal antibody–based regimens are frontline standards, the real-world value of adding a fourth drug (quadruplets vs. triplets) in this elderly population remains controversial. Older patients are underrepresented in clinical trials and frequently require dose modifications. Quadruplets may deepen responses (including higher rates of MRD negativity) and improve progression-free survival, but triplets remain attractive for patients in whom safety, convenience, and treatment continuity are priorities.  Thus, we evaluated the clinical characteristics, safety, and effectiveness of anti-CD38–containing quadruplets (quads) versus triplets in patients aged ≥75 years in routine practice.

Methods: The analysis included consecutive patients (≥75 years of age) who were treated with anti CD38-based therapies in a single center (Department of Clinical Therapeutics, Athens). Patients were divided in those treated with quads (i.e antiCD38 MoAb plus PI and lenalidomide/dexamethasone, n=27) and those treated with antiCD38-based triplets [n=76, of which antiCD38 MoAb plus lenalidomide/dexamethasone, (n=44) or antiCD38 MoAb plus PI+/-alkylator and dexamethasone, (n=32)].

Results: In total, 103 patients were included (quads: n=27; triplets: n=76). Baseline characteristics were generally balanced between groups, including gender (male: 58% vs. 62%), ECOG performance status (72% vs. 64%), and high comorbidity burden (CIRS score ≥7: 75% vs. 66%). Triplet-treated patients were slightly older (median age: 80 vs. 78.5 years; 53% vs. 35% aged ≥80 years, respectively). Renal impairment (creatinine>1.2 mg/dL: 54% vs. 47%; median eGFR: 60 vs.56 mL/min/1.73 m²), dialysis at diagnosis (4% vs. 9%), lytic bone disease (77% vs. 76%), anemia (Hb<10 g/dL: 39% vs. 44%), hypercalcemia (4% vs. 10%), extramedullary disease (4% vs. 3%), and high-risk cytogenetics (28% vs. 29%) were comparable. Quad-treated patients had lower rates of ISS stage 3 disease (35% vs. 59%, p=0.008), though R-ISS and R2-ISS stage distributions were similar. On intention to treat analysis, response rates were similar between groups with 73% of patients treated with quads achieving at least a VGPR vs 75% of patients treated with a CD38-based triplet; the respective overall response rates were 100% for quads and 90% for triplets. During first line therapy, similar proportion of patients required hospitalization for myeloma or treatment-related complications (31% versus 33%). After a median follow up of 24 months, 37 (36%) patients have progressed or died. The median estimated PFS for all patients is 52 months and the 1, 2 and 3-year PFS rate is 72%, 62% and 59%, respectively. The median PFS in the quad group has not been reached with 1,2 and 3 years PFS rate of 86%, 72% and 70% and is estimated to be 52 months in the CD38-based triplet group, with respective PFS rates of 67%, 58% and 55% (p=0.152). The overall survival has not been reached in either group and the 2- and 3-year survival rate is 84% and 72% vs 70% and 70% respectively (p=0.550).

Conclusion: In real-world patients aged ≥75 years with newly diagnosed MM, anti-CD38–based quadruplets are feasible and tolerable, demonstrating no significant increase in hospitalizations or severe toxicity compared to triplets. Importantly, quadruplet therapy significantly reduced early disease progression or death, supporting its role in fit and/or intermediate elderly patients.

Maria Gavriatopoulou, MD: Menarini Stemline - Honoraria; Swixx - Honoraria; Integris Pharma - Honoraria; GSK - Honoraria; Janssen-Cilag - Honoraria; J and J - Honoraria; Abbvie - Honoraria